2. Signaling Pathways
  3. Epigenetics
  4. Histone Methyltransferase
  5. Histone Methyltransferase Control

Histone Methyltransferase Control

Histone Methyltransferase Isoform Comparison

Histone Methyltransferase Controls (4):

Cat. No. Product Name Effect Purity
  • HY-107777A
    LLY-284
    		Control 99.11%
    LLY-284 is the diastereomer of LLY-283 with much less active. LLY-283 is a potent inhibitor of PRMT5. LLY-284 has the potential for the research of cancer diseases.
  • HY-103641B
    (2R)-Octyl-α-hydroxyglutarate sodium
    		Control
    (2R)-Octyl-α-hydroxyglutarate (sodium) is the sodium salt form of (2R)-Octyl-α-hydroxyglutarate. (2R)-Octyl-α-hydroxyglutarate has anti-inflammatory effects.
  • HY-117947
    (R)-OR-S1
    		Control
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
  • HY-155221
    UNC7145
    		Control
    UNC7145 is an inactive derivative of UNC6934 (HY-145103) that can be used as a negative control for the protein-protein inhibition activity of UNC6934.